1. Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma
    Sara Marinelli et al, 2014, BMC Cancer CrossRef
  2. Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership
    Lesley-Ann Miller et al, 2016, Journal of Managed Care & Specialty Pharmacy CrossRef
  3. Persistence and Compliance Among U.S. Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis
    Stacey A. DaCosta Byfield et al, 2015, Journal of Managed Care & Specialty Pharmacy CrossRef
  4. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
    Yoshihiko Tomita et al, 2017, Japanese Journal of Clinical Oncology CrossRef
  5. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition
    Rogerio B. Craveiro et al, 2017, Oncotarget CrossRef

  6. In vivo Screening of Natural Products Against Angiogenesis and Mechanisms of Anti-Angiogenic Activity of Deoxysappanone B 7,4ʹ-Dimethyl Ether


    Kan Chen et al, 2020, Drug Design, Development and Therapy CrossRef
  7. Identification of mundoserone by zebrafish in�vivo screening as a natural product with anti‑angiogenic activity
    Kan Chen et al, 2018, Experimental and Therapeutic Medicine CrossRef
  8. Use of Targeted Therapies for Advanced Renal Cell Carcinoma in the Asia-Pacific Region: Opinion Statement From China, Japan, Taiwan, Korea, and Australia
    Dingwei Ye et al, 2014, Clinical Genitourinary Cancer CrossRef
  9. Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma
    Anna M Czarnecka et al, 2017, Future Oncology CrossRef
  10. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis
    Kinga Krawczyk et al, 2023, Frontiers in Pharmacology CrossRef
  11. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
    P Ghatalia et al, 2015, British Journal of Cancer CrossRef
  12. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma
    Dong-Hoe Koo et al, 2016, Cancer Chemotherapy and Pharmacology CrossRef
  13. Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors
    Kriti Mittal et al, 2018, Clinical Genitourinary Cancer CrossRef
  14. Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis
    Xiaoyan Liu et al, 2017, Acta Oncologica CrossRef
  15. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
    Yoshihiko Tomita et al, 2020, Japanese Journal of Clinical Oncology CrossRef
  16. Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma
    Dalsan You et al, 2015, World Journal of Urology CrossRef
  17. Development of Chronic Myeloid Leukaemia in Patients Treated with Anti-VEGF Therapies for Clear Cell Renal Cell Cancer
    Anna M Czarnecka et al, 2015, Future Oncology CrossRef
  18. In Vitro Assays for Endothelial Cell Functions Required for Angiogenesis: Proliferation, Motility, Tubular Differentiation, and Matrix Proteolysis
    Suzanne A. Eccles et al, 2016, Angiogenesis Protocols CrossRef
  19. Risk factors and model for predicting toxicity‐related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Marina D. Kaymakcalan et al, 2016, Cancer CrossRef
  20. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study
    Yoshihiko Tomita et al, 2019, Japanese Journal of Clinical Oncology CrossRef
  21. Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
    Ana Elena Martín-Aguilar et al, 2021, BMC Cancer CrossRef
  22. Targeting the epidermal growth factor receptor in solid tumors: focus on safety
    Eleonora Lucchini et al, 2014, Expert Opinion on Drug Safety CrossRef
  23. Variants in angiogenesis-related genes and the risk of clear cell renal cell carcinoma
    C. Qin et al, 2014, Mutagenesis CrossRef
  24. Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma
    Hiroki Ishihara et al, 2018, Japanese Journal of Clinical Oncology CrossRef
  25. Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma
    Sandy Srinivas et al, 2018, Journal of Oncology Pharmacy Practice CrossRef
  26. Real‐life patterns of use, safety and effectiveness of sunitinib in first‐line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study
    Pernelle Noize et al, 2017, Pharmacoepidemiology and Drug Safety CrossRef